This page in English

Daniel Bergemalm

Befattning: Universitetslektor, adjungerad Organisation: Institutionen för medicinska vetenskaper

E-post: daniel.bergemalm@oru.se

Telefon: 019 302181

Rum: X2102

Forskningsämne

Medicin

Forskningsmiljöer

Nutrition-Gut-Brain Interactions Research Centre (NGBI)

Om Daniel Bergemalm

Daniel Bergemalm jobbar som specialistläkare och forskare inom medicinsk gastroenterologi och hepatologi vid Örebro Universitetssjukhus. Han disputerade 2010 vid Umeå Universitet med en avhandling om sjukdomsmekanismer vid amyotrofisk laterskleros. Efter flytt till Örebro 2010 har han parallellt med kliniskt arbete, haft en post-doctjänst med inriktning mot inflammatorisk tarmsjukdom.

Forskning

Daniels forskning handlar främst om att identifiera sjukdomsmekanismer och biomarkörer vid inflammatorisk tarmsjukdom (IBD). Pågående projekt berör kartläggning av proteinförändringar i blod och vävnad som uppstår innan sjukdomen bryter ut och vid tidpunkten för diagnos. Förhoppningen är att bättre förstå orsaker till sjukdomen och bidra till utveckling av verktyg för individ-anpassad behandling (precision medicine). Forskningen bedrivs inom ramen för en större forskargrupp vid Örebro Universitet fokuserad på ”inflammatorisk tarmsjukdom och translationell gastroenterologi” där det finns bred kompetens kring metoder inom både grundforskning och mer kliniknära forskning. Forskargruppen har ett stort både nationellt och internationellt samarbete.

Undervisning

Daniel Bergemalm deltar i undervisning på läkarprogrammet vid Örebro Universitet samt ansvarar för klinisk handledning av läkarstudenter inom medicinsk gastroenterologi och internmedicin.

Pågående projekt

Forskargrupper

Inflammatorisk tarmsjukdom och translationell gastroenterologi

Publikationer

Artiklar i tidskrifter | Konferensbidrag | Manuskript |

Artiklar i tidskrifter

Thunberg, J. , Grännö, O. , Bergemalm, D. , Eriksson, C. , Visuri, I. , Eberhardson, M. & Halfvarson, J. (2024). Comparative study of a point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels. Scandinavian Journal of Gastroenterology, 59 (2), 150-155.
Kalla, R. , Adams, A. T. , Nowak, J. K. , Bergemalm, D. , Vatn, S. , Ventham, N. T. , Kennedy, N. A. , Ricanek, P. & et al. (2023). Analysis of systemic epigenetic alterations in inflammatory bowel disease: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome. Journal of Crohn's & Colitis, 17 (2), 170-184.
Mahajna, H. , Verstockt, B. , Bergemalm, D. , Castiglione, F. , Rodríguez-Moranta, F. , Savarino, E. V. , Hoentjen, F. , Bessissow, T. & et al. (2023). Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. Journal of Crohn's & Colitis, 17 (5), 722-727.
Wallhuss, A. , Ottosson, J. , Cao, Y. , Andersson, E. , Bergemalm, D. , Eriksson, C. , Olén, O. , Szabo, E. & et al. (2023). Outcomes of bariatric surgery for patients with prevalent inflammatory bowel disease: A nationwide registry-based cohort study. Surgery, 174 (2), 144-151.
Shubhakar, A. , Jansen, B. C. , Adams, A. T. , Reiding, K. R. , Ventham, N. T. , Kalla, R. , Bergemalm, D. , Urbanowicz, P. A. & et al. (2023). Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease. Journal of Crohn's & Colitis, 17 (6), 919-932.
Eriksson, C. , Söderling, J. , Karlqvist, S. , Bröms, G. , Everhov, Å. H. , Bergemalm, D. , Ludvigsson, J. F. , Olén, O. & et al. (2023). Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease. Digestive Diseases and Sciences, 68 (7), 3119-3128.
Nowak, J. K. , Adams, A. T. , Kalla, R. , Lindstrøm, J. C. , Vatn, S. , Bergemalm, D. , Keita, Å. V. , Gomollón, F. & et al. (2022). Characterization of the circulating transcriptomic landscape in inflammatory bowel disease provides evidence for dysregulation of multiple transcription factors including NFE2, SPI1, CEBPB, and IRF2. Journal of Crohn's & Colitis, 16 (8), 1255-1268.
Juzenas, S. , Hübenthal, M. , Lindqvist, C. M. , Kruse, R. , Steiert, T. A. , Degenhardt, F. , Schulte, D. , Nikolaus, S. & et al. (2022). Detailed transcriptional landscape of peripheral blood points to increased neutrophil activation in treatment-naïve inflammatory bowel disease. Journal of Crohn's & Colitis, 16 (7), 1097-1109.
Moraes Holst, L. , Halfvarson, J. , Carlson, M. , Hedin, C. , Kruse, R. , Lindqvist, C. M. , Bergemalm, D. , Almér, S. & et al. (2022). Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis. Clinical and Experimental Gastroenterology, 15, 129-144.
Vatn, S. S. , Lindstrøm, J. C. , Moen, A. E. F. , Brackmann, S. , Tannæs, T. M. , Olbjørn, C. , Bergemalm, D. , Keita, Å. V. & et al. (2022). Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. Clinical and Experimental Gastroenterology, 15, 5-25.
Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Erikson, C. & et al. (2022). Orofacial Granulomatosis associated with Crohn's Disease: a multi-centre case series. Journal of Crohn's & Colitis, 16 (3), 430-435.
Salomon, B. , Bergemalm, D. & Halfvarson, J. (2022). Prognostic Biosignatures at Ileocecal Resection: Hope or Reality?. Journal of Crohn's & Colitis, 16 (6), 873-875.
Thunberg, J. , Björkqvist, O. , Hedin, C. R. H. , Forss, A. , Söderman, C. , Bergemalm, D. , Olén, O. , Hjortswang, H. & et al. (2022). Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterology journal, 10 (7), 631-639.
Eriksson, C. , Visuri, I. , Vigren, L. , Nilsson, L. , Kärnell, A. , Hjortswang, H. , Bergemalm, D. , Almer, S. & et al. (2021). Clinical effectiveness of golimumab in ulcerative colitis: a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG. Scandinavian Journal of Gastroenterology, 56 (11), 1304-1311.
Bergemalm, D. , Ramström, S. , Kardeby, C. , Hultenby, K. , Göthlin Eremo, A. , Sihlbom, C. , Bergström, J. , Palmblad, J. & et al. (2021). Platelet proteome and function in X-linked thrombocytopenia with thalassemia and in silico comparisons with gray platelet syndrome. Haematologica, 106 (11), 2947-2959.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2021). Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology, 14.
Kalla, R. , Adams, A. T. , Bergemalm, D. , Vatn, S. , Kennedy, N. A. , Ricanek, P. , Lindstrom, J. , Ocklind, A. & et al. (2021). Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. Journal of Crohn's & Colitis, 15 (5), 699-708.
Bergemalm, D. , Andersson, E. , Hultdin, J. , Eriksson, C. , Rush, S. T. , Kalla, R. , Adams, A. T. , Keita, Å. V. & et al. (2021). Systemic Inflammation in Preclinical Ulcerative Colitis. Gastroenterology, 161 (5), 1526-1539.e9.
Vatn, S. , Carstens, A. , Kristoffersen, A. B. , Bergemalm, D. , Casén, C. , Moen, A. E. F. , Tannaes, T. M. , Lindstrøm, J. & et al. (2020). Faecal microbiota signatures of IBD and their relation to diagnosis, disease phenotype, inflammation, treatment escalation and anti-TNF response in a European Multicentre Study (IBD-Character). Scandinavian Journal of Gastroenterology, 55 (10), 1146-1156.
Burisch, J. , Bergemalm, D. , Halfvarson, J. & Munkholm, P. (2020). The use of 5-aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study. United European Gastroenterology journal, 8 (8), 949-960.
Kalla, R. , Adams, A. T. , Ventham, N. T. , Kennedy, N. A. , White, R. , Clarke, C. , Ivens, A. , Bergemalm, D. & et al. (2020). Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in inflammatory bowel disease. Journal of Crohn's & Colitis, 14 (12), 1724-1733.
Zammit, S. C. , Ellul, P. , Girardin, G. , Valpiani, D. , Nielsen, K. R. , Olsen, J. , Goldis, A. , Lazar, D. & et al. (2018). Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. European Journal of Gastroenterology and Hepathology, 30 (11), 1297-1303.
Bergemalm, D. , Kruse, R. , Sapnara, M. , Halfvarson, J. & Hultgren Hörnquist, E. (2017). Elevated fecal peptidase D at onset of colitis in Galphai2(-/-) mice, a mouse model of IBD. PLOS ONE, 12 (3).
Adams, A. , Kalla, R. , Vatn, S. , Bonfiglio, F. , Nimmo, E. , Kennedy, N. , Ventham, N. , Vatn, M. & et al. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease - IBD Character. Journal of Crohn's & Colitis, 11 (Suppl. 1), S108-S108.
Eriksson, C. , Marsal, J. , Bergemalm, D. , Vigren, L. , Björk, J. , Eberhardson, M. , Karling, P. , Söderman, C. & et al. (2017). Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology, 52 (6-7), 722-729.
Ricanek, P. , Rahul, K. , Ber, Y. , Vatn, S. , Finnby, L. , Lindahl, T. , Bergemalm, D. , Carstens, A. & et al. (2017). Microbiota related disease activity and distribution in subgroups of inflammatory bowel disease. Journal of Crohn's & Colitis, 11 (Suppl. 1), S483-S484.
Kalla, R. , Adams, A. , Vatn, S. , Bergemalm, D. , Ricanek, P. , Lindström, J. , Ocklind, A. , Nordberg, N. & et al. (2017). Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: IBD Character study. Journal of Crohn's & Colitis, 11 (Suppl. 1), S13-S13.
Andersson, E. , Bergemalm, D. , Kruse, R. , Neumann, G. , D'Amato, M. , Repsilber, D. & Halfvarson, J. (2017). Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLOS ONE, 12 (10).

Konferensbidrag

Grännö, O. , Salomon, B. , Lindqvist, C. M. , Hedin, C. R. H. , Carlson, M. , Dannenberg, K. , Andersson, E. , Söderholm, J. D. & et al. (2024). Preclinical protein signatures in blood predict Crohn's disease and Ulcerative colitis several years before the diagnosis. I: Journal of Crohn's & Colitis. Konferensbidrag vid 9th Congress of ECCO, Stockholm, Sweden, February 21-24, 2024. (ss. I660-I661). Oxford University Press.
Salomon, B. , Carlson, M. , Bergemalm, D. , Hedin, C. R. H. , Söderholm, J. D. , Keita, Å. V. , Carsten, A. , Grip, O. & et al. (2024). Prognostic potential of mucosal proteins in Ulcerative Colitis. I: Journal of Crohn's & Colitis. Konferensbidrag vid 16th Congress of ECCO - European Crohn’s and Colitis Organisation (ECCO'21), (Virtual congress), July 2-3, 8-10, 2021. (ss. I544-I545). Oxford University Press.
Bazov, I. , Kruse, R. , Bergemalm, D. , Eriksson, C. , Hedin, C. R. , Carlson, M. , van Nieuwenhoven, M. , Keita, Å. V. & et al. (2023). A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts. I: Journal of Crohn's & Colitis. Konferensbidrag vid 18th Congress of ECCO Copenhagen, Denmark, March 1-4, 2023. (ss. I314-I315). Oxford University Press.
Mahajna, H. , Verstockt, B. , Bergemalm, D. , Castiglione, F. , Rodriguez-Moranta, F. , Savarino, E. V. , Hoentjen, F. , Bessissow, T. & et al. (2022). Idiopathic Thrombocytopenic Purpura associated with Inflammatory Bowel Disease: a multi-centre ECCO CONFER case series. I: Journal of Crohn's & Colitis. Konferensbidrag vid 17th Congress of ECCO Virtual, February 16-19, 2022. (ss. I561-I561). Oxford University Press.
Wong, S. Y. , Helmus, D. , Marlow, L. , Pazos, V. M. , Brann, S. , Wellens, J. , Kedia, S. , Mak, J. W. Y. & et al. (2022). Trans-continental analysis of over, 2000 Inflammatory Bowel Disease patients implicates geography, disease type, and exposure to immunosuppression as drivers of SARS-CoV-2 seroprevalence: data from the ICARUS-IBD Consortium. I: Journal of Crohn's & Colitis. Konferensbidrag vid 17th Congress of ECCO Virtual, February 16-19, 2022. (ss. I357-I358). Oxford University Press.
Kalla, R. , Adams, A. , Nowak, J. , Bergemalm, D. , Vatn, S. , Ventham, N. , Kennedy, N. , Ricanek, P. & et al. (2021). EPIGENETIC ALTERATIONS IN IBD: DEFINING GEOGRAPHICAL, GENETIC, AND IMMUNEIN-FLAMMATORY INFLUENCES ON THE CIRCULATING METHYLOME. I: Gut. Konferensbidrag vid BSG 2021 Annual Meeting Online, November 8-12, 2021. (ss. A5-A5). BMJ Publishing Group Ltd.
Phillips, F. , Verstockt, B. , Sladek, M. , de Boer, N. , Katsanos, K. , Karmiris, K. , Albshesh, A. , Eriksson, C. & et al. (2020). Orofacial granulomatosis in Crohn's disease: an ECCO CONFER multi-centre case series. I: Journal of Crohn's & Colitis. Oxford University Press.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Udumyan, R. , Karlén, P. , Grip, O. , Söderman, C. , Almer, S. & et al. (2020). Real-world effectiveness of vedolizumab in ulcerative colitis: Week 52 results from the Swedish multi-centre, prospective, observational SVEAH UC study. I: Journal of Crohn's & Colitis. Oxford University Press.
Bergemalm, D. , Andersson, E. , Karling, P. , Eriksson, C. , Repsilber, D. , Hultdin, J. , Halfvarson, J. & IBD Character Consortium, . (2019). Markers of systemic inflammation in preclinical ulcerative colitis. I: United European Gastroenterology journal. Sage Publications.
Eriksson, C. , Bergemalm, D. , Vigren, L. , Nilsson, L. , Visuri, I. , Hjortswang, H. , Udumyan, R. , Almer, S. & et al. (2018). Clinical effectiveness of golimumab: Interim analysis of the observational study of patients with ulcerative colitis on golimumab in the Swedish National Quality Registry for IBD-GO-SWIBREG. I: Journal of Crohn's & Colitis. Konferensbidrag vid 13th Congress of ECCO – European Crohn’s and Colitis Organisation, Vienna, Austria, February 14-17, 2018. (ss. S409-S410). Oxford University Press.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with Crohn's disease (SVEAH CD). I: Journal of Crohn's & Colitis. Oxford University Press.
Eriksson, C. , Rundquist, S. , Lykiardopoulos, V. , Karlen, P. , Grip, O. , Söderman, C. , Almer, S. , Hertervig, E. & et al. (2018). Clinical effectiveness of vedolizumab: Interim analysis of the Swedish observational study on vedolizumab assessing effectiveness and healthcare resource utilisation in patients with ulcerative colitis (SVEAH UC). I: Journal of Crohn's & Colitis. Oxford University Press.
Vatn, S. , Karlsson, M. C. , Carstens, A. , Detlie, T. E. , Ricanek, P. , Bergemalm, D. , Lindquist, C. M. , Jahnsen, J. & et al. (2018). Faecal microbiota in newly diagnosed Crohn's disease and its relation to treatment escalation. I: Journal of Crohn's & Colitis. Oxford University Press.
Vatn, S. , Karlsson, M. C. , Carstens, A. , Detlie, T. E. , Ricanek, P. , Lindquist, C. M. , Bergemalm, D. , Jahnsen, J. & et al. (2018). Faecal microbiota in treatment-naive ulcerative colitis and its relation to treatment escalation. I: Journal of Crohn's & Colitis. Oxford University Press.
Kalla, R. , Adams, A. T. , Vatn, S. , Bonfiglio, F. , Nimmo, E. R. , Kennedy, N. A. , Ventham, N. , Vatn, M. H. & et al. (2017). Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease – ibd character. I: Gut. Konferensbidrag vid Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017. (ss. A24-A25). BMJ Publishing Group Ltd.
Kalla, R. , Adams, A. T. , Vatn, S. , Bergemalm, D. , Ricanek, P. , Lindstrom, J. C. , Ocklind, A. , Nordberg, N. & et al. (2017). Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: ibd character study. I: Gut. Konferensbidrag vid Annual General Meeting of the British-Society-of-Gastroenterology (BSG), Manchester, England, June 19-22, 2017,. (ss. A202-A203). BMJ Publishing Group Ltd.
Andersson, E. , Bergemalm, D. , Kruse, R. , D'Amato, M. , Repsilber, D. & Halfvarson, J. (2016). Inflammatory biomarkers in serum discriminate Crohn's disease and ulcerative colitis from healthy controls. I: Journal of Crohn's & Colitis. Oxford University Press.
Kalla, R. , Ocklind, A. , Petren, C. , Nordberg, N. , Kennedy, N. , Ventham, N. , Pettersson, E. , Bergemalm, D. & et al. (2016). Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character Consortium. I: Journal of Crohn's & Colitis. Oxford University Press.
Kalla, R. , Kennedy, N. , Hjelm, F. , Modig, E. , Sundell, M. , Andreassen, B. , Bergemalm, D. , Ricanek, P. & et al. (2015). Proximity Extension Assay technology identifies novel serum biomarkers for predicting Inflammatory Bowel Disease: IBD Character Consortium. I: Journal of Crohn's & Colitis. Oxford University Press.

Manuskript

Carstens, A. , Björkqvist, O. , Lindqvist, C. M. , Rangel, I. , Repsilber, D. , Eriksson, C. , Bergemalm, D. , Bresso, F. & et al. Gut microbiota associated with treatment outcome to biological treatment in inflammatory bowel disease.
Koskela von Sydow, A. , Janbaz, C. , Bergemalm, D. & Ivarsson, M. IL-1α counteracts TGF-β regulated protein expression in human dermal fibroblasts.
Fart, F. , Amcoff, K. , Bergemalm, D. , Andersson, E. , Kalla, R. , Satsangi, J. , Lindqvist, C. M. , Halfvarson, J. & et al. Loss of tolerance to microbial antigens in preclinical Crohn’s disease differs with age at diagnosis : A twin study.